A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2004
10/28/2004	WO2004091537A2 Process for making gel films
10/28/2004	WO2004091536A2 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/28/2004	WO2004091533A2 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
10/28/2004	WO2004091532A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
10/28/2004	WO2004091530A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
10/28/2004	WO2004091529A2 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
10/28/2004	WO2004091528A2 Delivery systems of homogeneous thermoreversible alginate films
10/28/2004	WO2004091527A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
10/28/2004	WO2004091521A2 Methods and compositions for administration of trpv1 agonists
10/28/2004	WO2004091512A2 Abuse-resistant oral dosage forms and method of use thereof
10/28/2004	WO2004091500A2 Delivery of immune response modifier compounds
10/28/2004	WO2004091498A2 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
10/28/2004	WO2004091495A2 Compositions and methods related to production of erythropoietin
10/28/2004	WO2004091487A2 Hemophilia treatment by inhalation of coagulation factors
10/28/2004	WO2004091483A2 Once daily formulations of tetracyclines
10/28/2004	WO2004078121A3 Liposome composition for reduction of liposome-induced complement activation
10/28/2004	WO2004078111A3 Extended release minocycline compositions and processes for their preparation
10/28/2004	WO2004075828A3 Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
10/28/2004	WO2004074314A3 Chistosan-microparticles for ifn gene delivery
10/28/2004	WO2004073765A9 Drug delivery device and syringe for filling the same
10/28/2004	WO2004073738A3 Composition to be administered to a living being and method for marking agents
10/28/2004	WO2004073596A3 Vaccine composition comprising an hiv proteic antigen incorporated into multilamellar lipidic vesicles
10/28/2004	WO2004072085A3 Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations
10/28/2004	WO2004071736A3 Method of producing structures using centrifugal forces
10/28/2004	WO2004069135A3 Composition comprising a mixture of active principles, and method of preparation
10/28/2004	WO2004069132A3 Pharmaceutical preparations and a method for their production
10/28/2004	WO2004066925A3 Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
10/28/2004	WO2004064806A3 Process for modifying drug crystal formation
10/28/2004	WO2004062577A3 Two or more enteric materials to regulate drug release
10/28/2004	WO2004062560A3 Pharmaceutical composition
10/28/2004	WO2004062461A3 Therapeutic microfoam
10/28/2004	WO2004058140A3 Non-pegylated long-circulating liposomes
10/28/2004	WO2004056363A3 A physically and chemically stable nicotine-containing particulate material
10/28/2004	WO2004043140A3 Nutraceuticals and method of feeding aquatic animals
10/28/2004	WO2004041188A3 Compositions and methods for transdermal oxybutynin therapy
10/28/2004	WO2004017915A3 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition
10/28/2004	WO2004014318A3 Levothyroxine compositions and methods
10/28/2004	WO2004004682A3 Stable oily suspension of microgranules
10/28/2004	WO2003022125A3 Device and method to maintain vascularization near implant
10/28/2004	US20040215173 Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
10/28/2004	US20040215172 In situ blood vessel and aneurysm treatment
10/28/2004	US20040215171 Ingestible device for the release of substances at distinct locations in alimentary canal
10/28/2004	US20040215098 Skin patch including a temperature sensor
10/28/2004	US20040215066 Method of measuring the efficacy of a skin treatment program
10/28/2004	US20040215021 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
10/28/2004	US20040214899 aqueous solutions of citric acid, disodium phosphate and (S)-4-{{3-[2-(dimethylaminoethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, used for prophylaxis of headaches; drug delivery devices; nasal sprays
10/28/2004	US20040214860 Method for treating inflammatory bowel disease
10/28/2004	US20040214849 via injection or intravenous drip
10/28/2004	US20040214839 administering prostaglandin or agonist thereof and type IV selective phosphodiesterase (PDE) inhibitor to induce tolerance to antigens
10/28/2004	US20040214831 cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
10/28/2004	US20040214829 Compositions containing alpha-2-adrenergic agonist components
10/28/2004	US20040214797 Preserved pharmaceutical compositions comprising cyclodextrins
10/28/2004	US20040214772 aqueous solution of peptide YY receptor binding ligands or proteins, in sprayers for use in intranasal drug delivery
10/28/2004	US20040214770 Hemoactive compositions and methods for their manufacture and use
10/28/2004	US20040214759 Compositions and methods of use for a fibroblast growth factor
10/28/2004	US20040214754 Ophthalmic preparation containing glycomacropeptide
10/28/2004	US20040214753 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
10/28/2004	US20040214752 Dispersible pharmaceutical compositions
10/28/2004	US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist
10/28/2004	US20040213996 Having an ordered array structure of a plurality of one-dimensional pores, whose entrances have a functional group capable of bondingsplitting with a chemical based on a chemical reaction in response to an external stimulus; time release agents; drug delivery; heat resistance; dimerization
10/28/2004	US20040213855 Pharmaceutical composition for the treatment of acute disorders
10/28/2004	US20040213850 Sustained release delivery of a thrombin inhibitor
10/28/2004	US20040213849 Modified release dosage forms
10/28/2004	US20040213848 Modified release dosage forms
10/28/2004	US20040213847 Delayed release pharmaceutical compositions containing proton pump inhibitors
10/28/2004	US20040213846 exfoliated clay; useful in the application of agricultural chemicals directly onto the surfaces of leaves; or the application of active ingredients such as perfumes or pharmaceutical compounds onto skin
10/28/2004	US20040213845 comprises a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent
10/28/2004	US20040213844 one or more active principles solubilised, suspended or embedded in an amphiphilic matrix suitably formulated to modulate the in vitro and in vivo performances of those drugs which require repeated daily administrations or which have to be carried and released at specific sites of gastrointestinal tract
10/28/2004	US20040213843 Pharmaceutical formulation of gepirone for oral administration
10/28/2004	US20040213840 co-grinding a mixture of drug with a cross-linked polymeric carrier, followed by contacting with water or aqueous vapors causes decrease of insoluble crystalline fraction, increases amorphous fraction, and reduces both nanocrystal fraction and nanocrystals size of drug; increased bioavailabilty
10/28/2004	US20040213839 by maintaining the agent, a flavorant, and a cellulosic material in relatively close physical contact with one another in an oral dosage form
10/28/2004	US20040213838 film coated, chewable; contain less than about 5 mg of phenylalanine per each 10 grams of protein equivalent; minerals, vitamins; for providing nutrition for individuals afflicted with phenylketonuria
10/28/2004	US20040213837 Lipid encapsulating hydrophobic core; drugs; anesthetic
10/28/2004	US20040213836 DRUG DELIVERY; prolonging the time a pharmaceutical drug circulates in the blood of a subject, comprising: introducing into the subject's bloodstream a pharmaceutical composition comprising a liposome containing inventive compound
10/28/2004	US20040213835 Method to reduce liposome-induced complement activation
10/28/2004	US20040213834 Pharmacological preparation made from a nanopatriculate mesomorphous polyelectrolyte lipid complex and at least one active ingredient
10/28/2004	US20040213833 certain MMP inhibitory peptides improve the targeting of liposomes to cancer cells and enhance the uptake thereof by such cells
10/28/2004	US20040213832 non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at a rate and in an amount sufficient to induce and maintain analgesia over a period of at least three days, and up to 7 days to a patient in need thereof
10/28/2004	US20040213831 Tts with peel-off film with reduced resistance to tearing
10/28/2004	US20040213828 Pain relief lollipop compositions and methods
10/28/2004	US20040213798 Spray-dried alum compositions
10/28/2004	US20040213766 Compositions and methods for treating transplants
10/28/2004	US20040213745 Suitable for reconstitution and parenteral administration
10/28/2004	US20040213744 can be sprayed onto skin to form a breathable film or patch, which remains stable and in place over a period of days;comprises at least one medicament, at least one film former and at least one vehicle
10/28/2004	DE10392164T5 Oral verabreichbare pharmazeutische Formulierung Orally administrable pharmaceutical formulation
10/28/2004	DE10317461A1 Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
10/28/2004	CA2811272A1 Pharmaceutical formulations containing methylnaltrexone
10/28/2004	CA2803922A1 Once daily formulations of tetracyclines
10/28/2004	CA2718356A1 High concentration antibody and protein formulations
10/28/2004	CA2559670A1 Stable amlodipine maleate formulations
10/28/2004	CA2527175A1 Remedies for diseases to be applied to eye
10/28/2004	CA2523864A1 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
10/28/2004	CA2522802A1 Biologically active substance-immobilized device
10/28/2004	CA2522298A1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom
10/28/2004	CA2522297A1 Process for making gel films
10/28/2004	CA2522296A1 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
10/28/2004	CA2522294A1 Formulations and methods for treating rhinosinusitis
10/28/2004	CA2522293A1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
10/28/2004	CA2522112A1 Solid preparation for oral use
10/28/2004	CA2522100A1 Orally disintegrating tablets

1 ... 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 ... 2991